Lalistat 1 |
| Catalog No.GC44030 |
Lalistat 1 is an inhibitor of lysosomal acid lipase (LAL; IC50 = 68 nM using purified human LAL).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 501104-16-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lalistat 1 is an inhibitor of lysosomal acid lipase (LAL; IC50 = 68 nM using purified human LAL). [1] It is selective for LAL over human pancreatic and bovine milk lipoprotein lipases up to a concentration of 10 µM.[2] Lalistat 1 (0.01-10 µM) reduces cholesterol accumulation in lysosome-like storage organelles in GM03123 human fibroblast cells deficient in NPC1, a membrane protein found in late endosomes, in a concentration-dependent manner but has little effect on cholesterol accumulation in NPC1-deficient CHO cells.
Reference
[1]. Rosenbaum, A.I., Rujoi, M., Huang, A.Y., et al. Chemical screen to reduce sterol accumulation in Niemann-Pick C disease cells identifies novel lysosomal acid lipase inhibitors. Biochim Biophys. Acta. 1791(12), 1155-1165 (2009).
[2]. Rosenbaum, A.I., Cosner, C.C., Mariani, C.J., et al. Thiadiazole carbamates: Potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. J. Med. Chem. 53(14), 5281-5289 (2010).
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *